• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱癌的诊断与治疗:如何改善?

Diagnosis and treatment of bladder cancer: how can we improve?

机构信息

James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

出版信息

Postgrad Med. 2012 May;124(3):28-36. doi: 10.3810/pgm.2012.05.2545.

DOI:10.3810/pgm.2012.05.2545
PMID:22691896
Abstract

The majority of patients with bladder cancer will be diagnosed following an episode of hematuria. With few exceptions, these patients should be referred for a complete urologic evaluation, including a history and physical examination, flexible cystoscopy, imaging of the upper urinary tract, and optional urine cytology. Those found to have a bladder tumor should undergo transurethral resection for the combined purposes of initial staging and treatment. Delays in diagnosing invasive bladder cancer are associated with adverse outcomes. In this review, we cover the diagnosis and management of bladder cancer. In addition, we discuss ways to improve outcomes through increased public awareness, improvements in tumor detection, accurate staging, and regimented patient surveillance.

摘要

大多数膀胱癌患者将在血尿发作后被诊断出来。除了少数例外,这些患者都应接受全面的泌尿科评估,包括病史和体检、软性膀胱镜检查、上尿路影像学检查,以及可选的尿液细胞学检查。那些发现有膀胱肿瘤的患者应接受经尿道膀胱肿瘤切除术,以达到初步分期和治疗的双重目的。诊断浸润性膀胱癌的延迟与不良结果有关。在这篇综述中,我们讨论了膀胱癌的诊断和治疗。此外,我们还讨论了通过提高公众意识、改进肿瘤检测、准确分期和规范患者监测来改善结果的方法。

相似文献

1
Diagnosis and treatment of bladder cancer: how can we improve?膀胱癌的诊断与治疗:如何改善?
Postgrad Med. 2012 May;124(3):28-36. doi: 10.3810/pgm.2012.05.2545.
2
The diagnosis and staging of bladder cancer: from RBCs to TURs.
Urology. 2006 Mar;67(3 Suppl 1):3-8; discussion 8-10. doi: 10.1016/j.urology.2006.01.026.
3
Bladder cancer in 2010: how far have we come?2010 年膀胱癌:我们已经走了多远?
CA Cancer J Clin. 2010 Jul-Aug;60(4):244-72. doi: 10.3322/caac.20077. Epub 2010 Jun 21.
4
[Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].[非肌层浸润性膀胱癌的诊断与治疗——最新进展]
Aktuelle Urol. 2010 Sep;41(5):307-15. doi: 10.1055/s-0030-1262555. Epub 2010 Sep 7.
5
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.联合治疗浸润性膀胱癌保膀胱的长期疗效:MGH 经验。
Eur Urol. 2012 Apr;61(4):705-11. doi: 10.1016/j.eururo.2011.11.010. Epub 2011 Nov 12.
6
Imaging bladder cancer.膀胱癌影像学诊断。
Curr Opin Urol. 2010 Sep;20(5):409-13. doi: 10.1097/MOU.0b013e32833cbcb9.
7
Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?低级别非浸润性膀胱癌的随访负担能否通过光动力诊断、围手术期灌注、影像学和尿液标志物来减轻?
Curr Opin Urol. 2010 Sep;20(5):388-92. doi: 10.1097/MOU.0b013e32833cc9f4.
8
[Hematuria].[血尿]
Ther Umsch. 1996 Sep;53(9):672-5.
9
Diagnosis and treatment of bladder cancer.膀胱癌的诊断与治疗。
Am Fam Physician. 2009 Oct 1;80(7):717-23.
10
Bladder cancer: can imaging change patient management?膀胱癌:影像学检查能否改变患者的治疗方案?
Curr Opin Urol. 2008 Jan;18(1):98-104. doi: 10.1097/MOU.0b013e3282f13aac.

引用本文的文献

1
Role of miR-490-3p in blocking bladder cancer growth through targeting the RNA-binding protein PCBP2.miR-490-3p 通过靶向 RNA 结合蛋白 PCBP2 抑制膀胱癌生长的作用。
Kaohsiung J Med Sci. 2022 Jan;38(1):30-37. doi: 10.1002/kjm2.12457. Epub 2021 Oct 7.
2
Protein kinase TTK promotes proliferation and migration and mediates epithelial-mesenchymal transition in human bladder cancer cells.蛋白激酶TTK促进人膀胱癌细胞的增殖和迁移,并介导上皮-间质转化。
Int J Clin Exp Pathol. 2018 Oct 1;11(10):4854-4861. eCollection 2018.
3
PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells.
过氧化物酶体增殖物激活受体 γ 抑制可调控膀胱癌细胞的细胞周期、增殖和迁移。
J Cell Mol Med. 2019 May;23(5):3724-3736. doi: 10.1111/jcmm.14280. Epub 2019 Mar 25.
4
Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.BCL2、MCM7和CCNE1的表达上调表明在两种人膀胱癌细胞系中存在顺铂耐药性:T24顺铂敏感膀胱癌细胞系和T24R2顺铂耐药膀胱癌细胞系。
Investig Clin Urol. 2016 Jan;57(1):63-72. doi: 10.4111/icu.2016.57.1.63. Epub 2016 Jan 11.
5
Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.Xklp2的靶蛋白(TPX2)是一种微管相关蛋白,它在膀胱癌中促成恶性表型。
Tumour Biol. 2013 Dec;34(6):4089-100. doi: 10.1007/s13277-013-1000-z. Epub 2013 Jul 20.
6
Diagnostically challenging cases: what are atypia and dysplasia?诊断具有挑战性的病例:什么是不典型性和发育不良?
Urol Clin North Am. 2013 May;40(2):281-93. doi: 10.1016/j.ucl.2013.01.006. Epub 2013 Feb 26.